Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, single-arm, prospective phase II clinical study, which mainly
evaluates the efficacy and safety of pyrotinib maleate combined with oral vinorelbine in the
treatment of HER2-positive advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital